Menu Search
Equities

Telix Pharmaceuticals Ltd

TLX:ASX

Telix Pharmaceuticals Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)14.80
  • Today's Change-0.65 / -4.21%
  • Shares traded720.02k
  • 1 Year change+30.86%
  • Beta2.2974
Data delayed at least 20 minutes, as of May 17 2024 07:10 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in AUDIncome statement in AUDView more

Year on year Telix Pharmaceuticals Ltd grew revenues 213.90% from 160.10m to 502.55m while net income improved from a loss of 104.08m to a gain of 5.21m.
Gross margin62.56%
Net profit margin1.04%
Operating margin3.15%
Return on assets1.59%
Return on equity4.55%
Return on investment2.54%
More ▼

Cash flow in AUDView more

In 2023, Telix Pharmaceuticals Ltd increased its cash reserves by 5.94%, or 6.91m. The company earned 23.88m from its operations for a Cash Flow Margin of 4.75%. In addition the company generated 10.19m cash from financing while 25.49m was spent on investing.
Cash flow per share0.0369
Price/Cash flow per share425.16
Book value per share0.46
Tangible book value per share0.1212
More ▼

Balance sheet in AUDView more

Telix Pharmaceuticals Ltd has a Debt to Total Capital ratio of 10.49%, a lower figure than the previous year's 12.25%.
Current ratio1.43
Quick ratio1.32
Total debt/total equity0.1172
Total debt/total capital0.1049
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.